Anthem Biosciences Ltd. Fundamental Analysis
Anthem Biosciences Ltd. (ANTHEM.NS) shows moderate financial fundamentals with a PE ratio of 72.24, profit margin of 27.86%, and ROE of 21.64%. The company generates $21.3B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 91.3/100 based on profitability, valuation, growth, and balance sheet metrics. The A grade reflects excellent fundamentals and strong overall stability.
Fundamental Health Score
We analyze ANTHEM.NS's fundamental strength across five key dimensions:
Efficiency Score
ExcellentANTHEM.NS demonstrates superior asset utilization.
Valuation Score
ModerateANTHEM.NS shows balanced valuation metrics.
Growth Score
ModerateANTHEM.NS shows steady but slowing expansion.
Financial Health Score
ExcellentANTHEM.NS maintains a strong and stable balance sheet.
Profitability Score
ExcellentANTHEM.NS achieves industry-leading margins.
Key Financial Metrics
Is ANTHEM.NS Expensive or Cheap?
P/E Ratio
ANTHEM.NS trades at 72.24 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, ANTHEM.NS's PEG of 0.51 indicates potential undervaluation.
Price to Book
The market values Anthem Biosciences Ltd. at 14.05 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 47.09 times EBITDA. This signals the market has high growth expectations.
How Well Does ANTHEM.NS Make Money?
Net Profit Margin
For every $100 in sales, Anthem Biosciences Ltd. keeps $27.86 as profit after all expenses.
Operating Margin
Core operations generate 32.94 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $21.64 in profit for every $100 of shareholder equity.
ROA
Anthem Biosciences Ltd. generates $17.26 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Anthem Biosciences Ltd. generates strong operating cash flow of $6.34B, reflecting robust business health.
Free Cash Flow
Anthem Biosciences Ltd. generates strong free cash flow of $3.09B, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $5.50 in free cash annually.
FCF Yield
ANTHEM.NS converts 0.72% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
72.24
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.51
vs 25 benchmark
P/B Ratio
Price to book value ratio
14.05
vs 25 benchmark
P/S Ratio
Price to sales ratio
20.13
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.54
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.22
vs 25 benchmark
ROA
Return on assets percentage
0.17
vs 25 benchmark
ROCE
Return on capital employed
0.23
vs 25 benchmark
How ANTHEM.NS Stacks Against Its Sector Peers
| Metric | ANTHEM.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 72.24 | 29.63 | Worse (Expensive) |
| ROE | 21.64% | 223.00% | Weak |
| Net Margin | 27.86% | -38669.00% (disorted) | Strong |
| Debt/Equity | 0.02 | 0.82 | Strong (Low Leverage) |
| Current Ratio | 5.54 | 4.30 | Strong Liquidity |
| ROA | 17.26% | -379.00% (disorted) | Strong |
ANTHEM.NS outperforms its industry in 4 out of 6 key metrics, particularly excelling in Net Margin, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Anthem Biosciences Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation